Personalised Medicine and Diagnostics Europe 2011

Innovate in an era of cost-effectiveness: Realise the value of personalised medicine

• Discover how to strengthen your drug pipeline with companion diagnostics
• How to access the market
• Hear about the expectation of the pharmaceutical and diagnostics industry and payors
• Discover how pharmaceutical companies and diagnostics companies can work together successfully

Powerful reasons to attend the event:

Get the latest information on personalized medicine at your fingertips.

With access to exclusive keynote sessions and a very focused agenda, you’ll gain more in just 2 days than from weeks of market research or by purchasing expensive reports.

Expert speakers from Roche, Merck, Biomerieux, NICE, Pfizer and GSK will share their vision and best practice case studies. You can really profit from their knowledge and create powerful new strategies to overcome your business challenges.

·         Discover how to strengthen your drug pipeline with companion diagnostics

·         How to access the market

·         Hear about the expectation of the pharmaceutical and diagnostics industry and payors

·         Discover how pharmaceutical companies and diagnostics companies can work together successfully

Powerful reasons to attend the event:

Get the latest information on personalized medicine at your fingertips.

With access to exclusive keynote sessions and a very focused agenda, you’ll gain more in just 2 days than from weeks of market research or by purchasing expensive reports.

Expert speakers from Roche, Merck, Biomerieux, NICE, Pfizer and GSK will share their vision and best practice case studies. You can really profit from their knowledge and create powerful new strategies to overcome your business challenges.

Unrivalled networking.

Claim your seat at the table with all the key industry decision-makers and thought leaders to ensure you leave this meeting with your briefcase full of valuable contacts. Plus benefit from a number of structured 1-1 meetings during the networking breaks.

Senior level decision-makers in attendance.

Rub shoulders with the leading executives in personalized medicine from the U.S. and around the world to give your commercial enterprise a truly global perspective.

No sales pitches.

Personalized  Medicine & Diagnostics is an independently researched forum committed to equip you with the tools and expertise to drive your business forward. Every single presentation is rigorously reviewed to ensure an unrivalled high quality.

Speakers

·         Andrea Rappagliosi, Vice President European Government Affairs, GSK and President,

 

EuropaBio

·         Angela Flannery, Ph.D., Director  R&D Science Policy, AstraZeneca

·         Adam Heathfield,  Ph.D., Director Science Policy, Pfizer

·         Hans Winkler , Ph.D., Senior Director, Head of Oncology Biomarker Development, Ortho

Biotech Oncology, Johnson and Johnson Pharmaceutical R&D

·         Michael Motz, PhD, Director, Business Development and Partnering, Roche

·         Alexander Natz, LL.M., Secretary General, EUCOPE and Head of Brussels Office,

Bundesverband der Pharmazeutischen Industrie e.V. (BPI)

·         Iain D. Miller, Ph.D., Executive Director, Theranostics Strategy and Business Development,

Biomerieux

·         Stefan Müllner, Ph.D., CEO, Protagen AG

·         Charles Swanton, Ph.D., Head Translational Cancer Therapeutics, Cancer Research UK

·         Pietro Scalfaro, Ph.D., Director of Business Unit Diagnostics, Debiopharm

·         Nick Crabb, Ph.D., Director, Diagnostics Assessment Programme Centre for Health Technology

Evaluation, National Institute for Health and Clinical Excellence (NICE)

·         Annabel Bentley, M.D., Medical Director, Bupa

·         Gabriel Vargas, M.D., Ph.D., Biomarker Expert at Hoffmann-La Roche & Head of the CNS

Clinical Biomarker Group

·         John Lambert, MBBS, Ph.D., MMed, MFPM, FRACP, Vice President Chief Medical Officer Early

Phase Clinical Unit, Parexel

·         Ansar Jawaid, Ph.D., Global Diagnostics Brand Manager, Global Commercial, AstraZeneca

·         Louise Leong, Ph.D., Head of R&D, Association of the British Pharmaceutical Industry (ABPI)

·         Glyn Colebrooke, Ph.D., Senior Director Business Development, Philips

·         Matthew W. Beer, Ph.D., Director Oncology Marketing, Quest Diagnostics

·         Eddie Blair, Ph.D., Managing Director, Integrated Medicines

·         David Gonzalez de Castro, Ph.D., Head of Molecular Diagnostics, The Royal Marsden Hospital

and The Institute of Cancer Research

·         James Clark, Ph.D., Vice President Research and Development, MDx Health

·         Greg Maguire, Ph.D., CEO, BioRegenerative Sciences

Claim your seat at the table with all the key industry decision-makers and thought leaders to ensure you leave this meeting with your briefcase full of valuable contacts. Plus benefit from a number of structured 1-1 meetings during the networking breaks.

Senior level decision-makers in attendance.

Rub shoulders with the leading executives in personalized medicine from the U.S. and around the world to give your commercial enterprise a truly global perspective.

No sales pitches.

Personalized  Medicine & Diagnostics is an independently researched forum committed to equip you with the tools and expertise to drive your business forward. Every single presentation is rigorously reviewed to ensure an unrivalled high quality.

Speakers

·         Andrea Rappagliosi, Vice President European Government Affairs, GSK and President,

EuropaBio

·         Angela Flannery, Ph.D., Director  R&D Science Policy, AstraZeneca

·         Adam Heathfield,  Ph.D., Director Science Policy, Pfizer

·         Hans Winkler , Ph.D., Senior Director, Head of Oncology Biomarker Development, Ortho

Biotech Oncology, Johnson and Johnson Pharmaceutical R&D

·         Michael Motz, PhD, Director, Business Development and Partnering, Roche

·         Alexander Natz, LL.M., Secretary General, EUCOPE and Head of Brussels Office,

Bundesverband der Pharmazeutischen Industrie e.V. (BPI)

·         Iain D. Miller, Ph.D., Executive Director, Theranostics Strategy and Business Development,

Biomerieux

·         Stefan Müllner, Ph.D., CEO, Protagen AG

·         Charles Swanton, Ph.D., Head Translational Cancer Therapeutics, Cancer Research UK

·         Pietro Scalfaro, Ph.D., Director of Business Unit Diagnostics, Debiopharm

·         Nick Crabb, Ph.D., Director, Diagnostics Assessment Programme Centre for Health Technology

Evaluation, National Institute for Health and Clinical Excellence (NICE)

·         Annabel Bentley, M.D., Medical Director, Bupa

·         Gabriel Vargas, M.D., Ph.D., Biomarker Expert at Hoffmann-La Roche & Head of the CNS

Clinical Biomarker Group

·         John Lambert, MBBS, Ph.D., MMed, MFPM, FRACP, Vice President Chief Medical Officer Early

Phase Clinical Unit, Parexel

·         Ansar Jawaid, Ph.D., Global Diagnostics Brand Manager, Global Commercial, AstraZeneca

·         Louise Leong, Ph.D., Head of R&D, Association of the British Pharmaceutical Industry (ABPI)

·         Glyn Colebrooke, Ph.D., Senior Director Business Development, Philips

·         Matthew W. Beer, Ph.D., Director Oncology Marketing, Quest Diagnostics

·         Eddie Blair, Ph.D., Managing Director, Integrated Medicines

·         David Gonzalez de Castro, Ph.D., Head of Molecular Diagnostics, The Royal Marsden Hospital

and The Institute of Cancer Research

·         James Clark, Ph.D., Vice President Research and Development, MDx Health

·         Greg Maguire, Ph.D., CEO, BioRegenerative Sciences